News
Lorraine Nolan has been appointed to the high-profile role as head of the EU’s drug agency. She was appointed executive director of the European Union Drugs Agency after receiving a two-thirds ...
1d
Pharmaceutical Technology on MSNAveroa secures EC authorisation for oral CKD treatmentThe European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) ...
XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia ; Averoa submitted XOANACYL for UK approval via MHRA’ ...
Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in ...
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as ...
Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy. PolTREG established Immuthera ( in Delaware to expand its prese ...
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines ...
The positive opinion for Zenrelia, or ilunocitinib, opens the way for the product's marketing authorization in the European Union in the next 60 days. The company said it expects to launch Zenrelia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results